Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
From the American Academy of PediatricsPolicy Statement

Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth

COMMITTEE ON INFECTIOUS DISEASES and COMMITTEE ON FETUS AND NEWBORN
Pediatrics September 2017, 140 (3) e20171870; DOI: https://doi.org/10.1542/peds.2017-1870
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

After the introduction of the hepatitis B vaccine in the United States in 1982, a greater than 90% reduction in new infections was achieved. However, approximately 1000 new cases of perinatal hepatitis B infection are still identified annually in the United States. Prevention of perinatal hepatitis B relies on the proper and timely identification of infants born to mothers who are hepatitis B surface antigen positive and to mothers with unknown status to ensure administration of appropriate postexposure immunoprophylaxis with hepatitis B vaccine and immune globulin. To reduce the incidence of perinatal hepatitis B transmission further, the American Academy of Pediatrics endorses the recommendation of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that all newborn infants with a birth weight of greater than or equal to 2000 g receive hepatitis B vaccine by 24 hours of age.

  • Abbreviations:
    ACIP —
    Advisory Committee on Immunization Practices
    Anti-HBs —
    hepatitis B surface antibody
    HBeAg —
    hepatitis B e antigen
    HBIG —
    hepatitis B immune globulin
    HBsAg —
    hepatitis B surface antigen
  • Approximately 1000 new cases of perinatal hepatitis B infection are identified annually in the United States.1,2 Chronic hepatitis B infection occurs in up to 90% of infants infected with hepatitis B at birth or in the first year of life. When untreated, approximately 25% ultimately will die of hepatocellular carcinoma or liver cirrhosis. In the absence of postexposure prophylaxis at birth, the risk of perinatal transmission is substantial when an infant is born to a mother who is hepatitis B surface antigen (HBsAg) positive. The proportion of infants acquiring infection in this circumstance ranges from approximately 30% when mothers are hepatitis B e antigen (HBeAg) (a marker of infectivity) negative to approximately 85% when mothers are HBeAg positive. Because maternal HBeAg status frequently is unknown, the true risk to an individual newborn infant also generally is unknown. Postexposure prophylaxis is highly effective. Hepatitis B vaccine alone is 75% to 95% effective in preventing perinatal hepatitis B transmission when given within 24 hours of birth.3,4 When postexposure prophylaxis with both hepatitis B vaccine and hepatitis B immune globulin (HBIG) is given, is timed appropriately, and is followed by completion of the infant hepatitis B immunization series, perinatal infection rates range from 0.7% to 1.1%.5,6 These findings are the basis for the rationale for the current change in the recommendation regarding birth vaccination.

    Prevention of perinatal transmission of hepatitis B is part of a national strategy for hepatitis B prevention that relies on testing all pregnant women for hepatitis B infection by testing women for HBsAg routinely during pregnancy and providing appropriate and timely prophylaxis to all newborn infants.6 Appropriate prophylaxis consists of HBIG and/or hepatitis B vaccine, depending on the HBsAg status of the mother and the weight of the infant (Fig 1). The birth dose of hepatitis B vaccine is a critical safety net to protect infants born to hepatitis B–infected mothers not identified at the time of birth. The birth dose can prevent infection of infants born to infected mothers in situations in which the mother’s results are never obtained, are misinterpreted, are falsely negative, are transcribed or reported to the infant care team inaccurately, or simply not communicated to the nursery. The Immunization Action Coalition reported greater than 500 such errors in perinatal hepatitis B prevention from 1999 to 2002.7 The birth dose also provides protection to infants at risk from household exposure after the perinatal period. For infants born to HBsAg-negative mothers, the birth dose is the beginning of appropriate lifelong prophylaxis. Because the consequences of perinatally acquired hepatitis B are enduring and potentially fatal, the safety net of the birth dose is critically important. The incidence of new hepatitis B infections has increased in some states as a result of the opioid epidemic in the United States,8 underscoring the urgency of improving perinatal prevention strategies.

    FIGURE 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1

    Administration of the birth dose of hepatitis B vaccine by maternal HBsAg status.

    Hepatitis B antiviral therapy now is offered during pregnancy to hepatitis B–infected women with high hepatitis B viral loads. Antiviral therapy started from 30 to 32 weeks’ gestational age and continued until postpartum week 4 in the mother, in addition to newborn prophylaxis with hepatitis B vaccine and HBIG, has been associated with significantly reduced rates of perinatal hepatitis B virus transmission from highly viremic mothers.9 There is no evidence, however, that maternal antenatal treatment alone without infant prophylaxis is sufficient to reduce the risk for perinatal transmission.10

    The US Department of Health and Human Services has set a goal of 0 perinatal hepatitis B transmission in the United States by 2020.6 Although 95% of infants born to infected women who are identified by the Centers for Disease Control and Prevention’s Perinatal Hepatitis B Prevention Program do receive prophylaxis with HBIG and hepatitis B vaccine within 12 hours of birth, the overall hepatitis B immunization rate of newborn infants is suboptimal.11 In 2005, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) issued hepatitis B vaccine recommendations that contained permissive language around administration of the birth dose of hepatitis B vaccine, allowing practitioners the option to delay this dose.5 By 2014, a quality improvement study found that only 72% of infants received the birth dose of hepatitis B vaccine, which is less than the Healthy People 2020 target of 85%.12 In October 2016, the ACIP rescinded the permissive language and instead stated the following: “For all medically stable infants weighing greater than or equal to 2000 grams at birth and born to HBsAg-negative mothers, the first dose of vaccine should be administered within 24 hours of birth. Only single-antigen hepatitis B vaccine should be used for the birth dose.”13,14

    Recommendations

    The American Academy of Pediatrics Committee on Infectious Diseases and the Committee on Fetus and Newborn support removal of permissive language for delaying the birth dose of hepatitis B vaccine, endorse the recommendation of the ACIP for giving the birth dose within the first 24 hours of life in all medically stable infants weighing greater than or equal to 2000 g, and provide guidance for implementation.15

    Vaccine Issues

    After completion of a 3- or 4-dose hepatitis B vaccine series, 98% of healthy term infants achieve protective antibody concentrations. Protection may be lower in infants with birth weights less than 2000 g.5 The optimal time to perform serologic testing to detect a vaccine response in infants is 1 to 2 months after the final dose of the hepatitis B vaccine series. Recommendations for postvaccination serologic testing of infants born to hepatitis B–infected mothers have been updated recently.16 For infants born to HBsAg-positive mothers, postvaccination serologic testing by measuring hepatitis B surface antibody (anti-HBs) to document protection and HBsAg to rule out perinatal infection now is recommended at 9 to 12 months of age instead of 9 to 18 months. Infants who are HBsAg negative with anti-HBs levels less than 10 mIU/mL (nonprotective) require additional vaccine doses. The ACIP considered revaccination strategies in February 2017 and recommended that HBsAg-negative infants with anti-HBs levels less than 10 mIU/mL receive a single additional dose of hepatitis B vaccine and be retested for anti-HBs 1 to 2 months after that vaccine dose. If the anti-HBs level is still less than 10 mIU/mL, the infant should receive 2 additional doses of hepatitis B vaccine followed by retesting 1 to 2 months later. Infants with anti-HBs levels less than 10 mIU/mL after 2 3-dose series of hepatitis B vaccine are nonresponders, and available data do not suggest benefit from additional vaccinations. The ACIP noted that, on the basis of clinical circumstance or family preference, HBsAg-negative infants with anti-HBs levels less than 10 mIU/mL may be vaccinated instead with a second complete series followed by postvaccination testing 1 to 2 months after the final dose.

    Hepatitis B vaccine is well tolerated in infants.17,18 Commonly reported mild adverse events after hepatitis B vaccination in people of all ages from postmarketing surveillance data include pain (3%–29%), erythema (3%), swelling (3%), fever (1%–6%), and headache (3%). Safety of hepatitis B vaccines has been examined extensively; no evidence of a causal association between receipt of hepatitis B vaccine and neonatal sepsis or death, rheumatoid arthritis, Bell’s palsy, autoimmune thyroid disease, hemolytic anemia in children, anaphylaxis, optic neuritis, Guillain-Barré syndrome, sudden-onset sensorineural hearing loss, or other chronic illnesses has been demonstrated through analysis of data from the Vaccine Safety Datalink.5 Perinatal hepatitis B–prevention strategies are considered cost-effective, with a cost-effectiveness ratio of $2600 per quality-adjusted life-year.19

    Implementation

    The following are key steps for implementing appropriate administration of the birth dose of hepatitis B vaccine (see also Fig 1):

    • Identify HBsAg-positive mothers before delivery and document maternal HBsAg status in infant records;

    • Resolve unknown HBsAg status of mothers as soon as possible around delivery, and document maternal status in infant records;

    • For all infants born to HBsAg-positive mothers, administer both hepatitis B vaccine and HBIG within 12 hours of birth, regardless of any maternal antenatal treatment with antiviral medications;

    • For all infants with birth weight greater than or equal to 2000 g born to HBsAg-negative mothers, administer hepatitis B vaccine as a universal routine prophylaxis within 24 hours of birth;

    • For all infants with birth weight less than 2000 g born to HBsAg-negative mothers, administer hepatitis B vaccine as a universal routine prophylaxis at 1 month of age or at hospital discharge (whichever is first);

    • For all infants born to HBsAg-unknown mothers, administer hepatitis B vaccine within 12 hours of birth, and:

      • For infants with birth weight greater than or equal to 2000 g, administer HBIG by 7 days of age or by hospital discharge (whichever occurs first) if maternal HBsAg status is confirmed positive or remains unknown;

      • For infants with birth weight less than 2000 g, administer HBIG by 12 hours of birth unless maternal HBsAg status is confirmed negative by that time;

    • Document infant vaccination accurately in birth hospital records and in the appropriate CDC Immunization Information Systems and state immunization registry. Review documentation accuracy periodically and address identified errors; and

    • Develop procedures to educate all personnel involved in newborn care about recommendations for the birth dose of hepatitis B vaccine, including those personnel who provide care at planned home births.

    Committee on Fetus and Newborn, 2016–2017

    Kristi Watterberg, MD, FAAP, Chairperson

    William Benitz, MD, FAAP

    Ivan Hand, MD, FAAP

    Eric Eichenwald, MD, FAAP

    Brenda Poindexter, MD, FAAP

    Dan L. Stewart, MD, FAAP

    Susan W. Aucott, MD, FAAP

    Karen M. Puopolo, MD, PhD, FAAP

    Jay P. Goldsmith, MD, FAAP

    Liaisons

    Kasper S. Wang, MD, FAAP – American Academy of Pediatrics Section on Surgery

    Thierry Lacaze, MD – Canadian Paediatric Society

    Maria Ann Mascola, MDD – American College of Obstetricians and Gynecologists

    Tonse N.K. Raju, MD, DCH – National Institutes of Health

    Wanda D. Barfield, MD, MPH, FAAP, RADM USPHS – Centers for Disease Control and Prevention

    Erin Keels, MS, APRN, NNP-BC – National Association of Neonatal Nurses

    Staff

    Jim Couto, MA

    Committee on Infectious Diseases, 2016–2017

    Carrie L. Byington, MD, FAAP, Chairperson

    Yvonne A. Maldonado, MD, FAAP, Vice Chairperson

    Elizabeth D. Barnett MD, FAAP

    James D. Campbell, MD, FAAP

    H. Dele Davies, MD, MS, MHCM, FAAP

    Ruth Lynfield, MD, FAAP

    Flor M. Munoz, MD, FAAP

    Dawn Nolt, MD, MPH, FAAP

    Ann-Christine Nyquist, MD, MSPH, FAAP

    Sean O’Leary, MD, MPH, FAAP

    Mobeen H. Rathore, MD, FAAP

    Mark H. Sawyer, MD, FAAP

    William J. Steinbach, MD, FAAP

    Tina Q. Tan, MD, FAAP

    Theoklis E. Zaoutis, MD, MSCE, FAAP

    Ex Officio

    David W. Kimberlin, MD, FAAP – Red Book Editor

    Michael T. Brady, MD, FAAP – Red Book Associate Editor

    Mary Anne Jackson, MD, FAAP – Red Book Associate Editor

    Sarah S. Long, MD, FAAP – Red Book Associate Editor

    Henry H. Bernstein, DO, MHCM, FAAP – Red Book Online Associate Editor

    H. Cody Meissner, MD, FAAP – Visual Red Book Associate Editor

    Liaisons

    Douglas Campos-Outcalt, MD, MPA – American Academy of Family Physicians

    Amanda C. Cohn, MD, FAAP – Centers for Disease Control and Prevention

    Karen M. Farizo, MD – US Food and Drug Administration

    Marc Fischer, MD, FAAP – Centers for Disease Control and Prevention

    Bruce G. Gellin, MD, MPH – National Vaccine Program Office

    Richard L. Gorman, MD, FAAP – National Institutes of Health

    Natasha Halasa, MD, MPH, FAAP – Pediatric Infectious Diseases Society

    Joan L. Robinson, MD – Canadian Paediatric Society

    Jamie Deseda-Tous, MD – Sociedad Latinoamericana de Infectologia Pediatrica (SLIPE)

    Geoffrey R. Simon, MD, FAAP – Committee on Practice Ambulatory Medicine

    Jeffrey R. Starke, MD, FAAP – American Thoracic Society

    Staff

    Jennifer M. Frantz, MPH

    Footnotes

    • This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

    • Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

    • The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

    • All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

    • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

    • FUNDING: No external funding.

    • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

    References

    1. ↵
      1. Centers for Disease Control and Prevention, Division of Viral Hepatitis
      . Surveillance for viral hepatitis—United States 2014. Revised September 26, 2016. Available at: https://www.cdc.gov/hepatitis/statistics/2014surveillance/. Accessed March 23, 2017
    2. ↵
      1. Ko SC,
      2. Fan L,
      3. Smith EA,
      4. Fenlon N,
      5. Koneru AK,
      6. Murphy TV
      . Estimated annual perinatal hepatitis b virus infections in the United States, 2000-2009. J Pediatric Infect Dis Soc. 2016;5(2):114–121pmid:26407247
      OpenUrlCrossRefPubMed
    3. ↵
      1. Beasley RP,
      2. Hwang LY,
      3. Lee GC, et al
      . Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099–1102pmid:6138642
      OpenUrlPubMed
    4. ↵
      1. Lee C,
      2. Gong Y,
      3. Brok J,
      4. Boxall EH,
      5. Gluud C
      . Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537):328–336pmid:16443611
      OpenUrlAbstract/FREE Full Text
    5. ↵
      1. Mast EE,
      2. Margolis HS,
      3. Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP)
      . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54(RR-16):1–31pmid:16371945
      OpenUrlPubMed
    6. ↵
      1. US Department of Health and Human Services
      . Action plan for the prevention, care, & treatment of viral hepatitis. Updated 2014–2016. Available at: https://www.hhs.gov/sites/default/files/viral-hepatitis-action-plan.pdf. Accessed March 23, 2017
    7. ↵
      1. Immunization Action Coalition
      . Reducing medical errors: case reports. Available at: www.immunize.org/protect-newborns/guide/chapter2/case-reports.pdf. Accessed March 23, 2017
    8. ↵
      1. Harris AM,
      2. Iqbal K,
      3. Schillie S, et al
      . Increases in acute hepatitis b virus infections — Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR Morb Mortal Wkly Rep. 2016;65(3):47–50pmid:26821369
      OpenUrlPubMed
    9. ↵
      1. Pan CQ,
      2. Duan Z,
      3. Dai E, et al; China Study Group for the Mother-to-Child Transmission of Hepatitis B
      . Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374(24):2324–2334pmid:27305192
      OpenUrlPubMed
    10. ↵
      1. Chen HL,
      2. Lee CN,
      3. Chang CH, et al; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT Study); Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV PreMIT Study
      . Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62(2):375–386pmid:25851052
      OpenUrlCrossRefPubMed
    11. ↵
      1. Schillie S,
      2. Walker T,
      3. Veselsky S, et al
      . Outcomes of infants born to women infected with hepatitis B. Pediatrics. 2015;135(5). Available at: www.pediatrics.org/cgi/content/full/135/5/e1141pmid:25896839
      OpenUrlAbstract/FREE Full Text
    12. ↵
      1. Hill HA,
      2. Elam-Evans LD,
      3. Yankey D,
      4. Singleton JA,
      5. Kolasa M
      . National, state, and selected local area vaccination coverage among children aged 19-35 months - United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(33):889–896pmid:26313470
      OpenUrlCrossRefPubMed
    13. ↵
      1. Kim DK,
      2. Riley LE,
      3. Harriman KH,
      4. Hunter P,
      5. Bridges CB
      . Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2017. . MMWR Morb Mortal Wkly Rep. 2017; 66(5);136–138
      OpenUrl
    14. ↵
      1. US Department of Health and Human Services, Centers for Disease Control and Prevention
      . Advisory committee on immunization practices. summary report. 2016. Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2016-10.pdf. Accessed May 3, 2017
    15. ↵
      1. Committee on Infectious Diseases
      . Recommended childhood and adolescent immunization schedule—United States, 2017. Pediatrics. 2017;139(3):e20164007pmid:28167516
      OpenUrlFREE Full Text
    16. ↵
      1. Schillie S,
      2. Murphy TV,
      3. Fenlon N,
      4. Ko S,
      5. Ward JW
      . Update: shortened interval for postvaccination serologic testing of infants born to hepatitis B-infected mothers. MMWR Morb Mortal Wkly Rep. 2015;64(39):1118–1120pmid:26447601
      OpenUrlCrossRefPubMed
    17. ↵
      1. Eriksen EM,
      2. Perlman JA,
      3. Miller A, et al
      . Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project. Pediatr Infect Dis J. 2004;23(7):656–662pmid:15247605
      OpenUrlCrossRefPubMed
    18. ↵
      1. Lewis E,
      2. Shinefield HR,
      3. Woodruff BA, et al; Vaccine Safety Datalink Workgroup
      . Safety of neonatal hepatitis B vaccine administration. Pediatr Infect Dis J. 2001;20(11):1049–1054pmid:11734710
      OpenUrlCrossRefPubMed
    19. ↵
      1. Barbosa C,
      2. Smith EA,
      3. Hoerger TJ, et al
      . Cost-effectiveness analysis of the national perinatal hepatitis B prevention program. Pediatrics. 2014;133(2):243–253pmid:24394684
      OpenUrlAbstract/FREE Full Text
    • Copyright © 2017 by the American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 140, Issue 3
    1 Sep 2017
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth
    COMMITTEE ON INFECTIOUS DISEASES, COMMITTEE ON FETUS AND NEWBORN
    Pediatrics Sep 2017, 140 (3) e20171870; DOI: 10.1542/peds.2017-1870

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth
    COMMITTEE ON INFECTIOUS DISEASES, COMMITTEE ON FETUS AND NEWBORN
    Pediatrics Sep 2017, 140 (3) e20171870; DOI: 10.1542/peds.2017-1870
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Abstract
      • Recommendations
      • Committee on Fetus and Newborn, 2016–2017
      • Liaisons
      • Staff
      • Committee on Infectious Diseases, 2016–2017
      • Ex Officio
      • Liaisons
      • Staff
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • Timely Hepatitis B Birth Dose Receipt for Newborns: Within 24 Hours
    • The Importance of Hepatitis B Antigen Screening in Pregnancy
    • Improving Birth Dose Hepatitis B Vaccination Rates: A Quality Improvement Intervention
    • Providing Care for Infants Born at Home
    • Update on Prenatal Laboratory Screening: Joint Commission Required Elements
    • Parental Refusal of Standard-of-Care Prophylactic Newborn Practices: In One Centers Experience, Many Refuse One but Few Refuse All
    • Factors Associated With Refusal of Intramuscular Vitamin K in Normal Newborns
    • Google Scholar

    More in this TOC Section

    • Recommended Childhood and Adolescent Immunization Schedule: United States, 2021
    • Ethical Considerations in Pediatricians’ Use of Social Media
    • 2021 Recommendations for Preventive Pediatric Health Care
    Show more From the American Academy of Pediatrics

    Similar Articles

    Subjects

    • Current Policy
    • Infectious Disease
      • Infectious Disease
    • AAP Policy Collections by Authoring Entities
      • Committee on Infectious Diseases
      • Committee on Fetus & Newborn
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics